<DOC>
	<DOCNO>NCT00325325</DOCNO>
	<brief_summary>The purpose study address pharmacokinetic ( PK ) profile everolimus tacrolimus combination de novo kidney transplant recipient , compare 1.5 3 mg per day everolimus fixed dos . For comparison purpose , pharmacokinetic profile perform first dose ( abbreviate ) , 4th day , 14th day , 42nd day post-transplantation .</brief_summary>
	<brief_title>Pharmacokinetic Study Combination Everolimus-Tacrolimus</brief_title>
	<detailed_description>To address pharmacokinetic profile everolimus tacrolimus combination de novo kidney transplant recipient , compare 1.5 3 mg per day everolimus fixed dos . For comparison purpose , pharmacokinetic profile perform first dose ( abbreviate ) , 4th day , 14th day , 42nd day post-transplantation . Patients receive triple therapy steroid , tacrolimus everolimus . Tacrolimus administer dose 0.15 mg/kg/day achieve 10-15 ng/ml 14 day , 5-10 thereafter . During first 6 week ( PK study period ) everolimus assign fix dose 0.75 1.5 mg bid . After day 42 , everolimus adjust 3-8 ng/ml tacrolimus minimize optimize graft function . Efficacy safety parameter 6 month post-transplantation secondary endpoint .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Kidney transplant recipient age 1865 year old presume immediately function graft Nonfunctioning kidney</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Kidney Transplantation</keyword>
</DOC>